Emerging Analytical Techniques in Metabolomics for Cancer Diagnosis and Prognosis

Introduction: Metabolomics, utilizing sophisticated analytical platforms such as mass spectrometry (MS), is critical for uncovering diagnostic and prognostic cancer biomarkers. This review highlights cutting-edge analytical techniques and their role in biomarker discovery for early detection, prognosis, and therapeutic monitoring, focusing on lung, breast, bladder, prostate, and ovarian cancers. Methods: This review was conducted using studies published over the last five years from PubMed, Scopus, Web of Science, and Google Scholar. Inclusion criteria focused on advanced metabolomics platforms, specifically Nuclear Magnetic Resonance (NMR), Gas Chromatography– Tandem Mass Spectrometry (GC-MS/MS), Capillary Electrophoresis–Tandem Mass Spectrometry (CE-MS/MS), and Liquid Chromatography–Tandem Mass Spectrometry (LCMS/ MS), for cancer biomarker identification. Results: Emerging technologies and automated workflows have substantially improved metabolite detection, quantification, and interpretation. These innovations have facilitated the discovery of distinct metabolic signatures associated with tumor progression and drug resistance. Integration with systems biology has further supported the development of non-invasive diagnostic and prognostic tools. Discussion: Advanced analytical techniques, including MS and NMR, are transforming precision oncology through robust biomarker discovery. However, challenges such as the complexity of cancer metabolic pathways, inter-sample variability, and the lack of standardized protocols remain significant barriers to clinical translation. Conclusion: Future developments, particularly multi-omics integration and real-time metabolite monitoring, are expected to enhance the clinical utility of metabolomics, paving the way for its full integration into personalized cancer diagnosis, prognosis, and therapy.